Methods for preventing biofilm formation
AssigneeSanofi
InventorsAstrid Rey, Sylvie Lefort, Laurent Fraisse, Jeremy Yethon
Life of this patent
Estimating the term…
Abstract
Provided are methods for the treatment or prevention of microbial infections (e.g., nocosomial infection) in which the underlying pathology involves a PNAG-containing microbial bio film. The methods the invention generally involve administering to the subject an effective amount of an antibody that specifically binds to PNAG and disrupt or inhibit formation of PNAG-containing microbial bio films. Such methods are particularly useful for the treatment of nosocomial staphylococcus (e.g., S. epidermidis and S. aureus) infections.
Claims41
A method of preventing a nocosomial infection comprising:
- identifying a subject at risk of developing an poly-N-acetyl glucosamine (PNAG)-containing microbial biofilm from a medical procedure;
- and
- administering to the subject an effective amount of an antibody that specifically binds to PNAG and inhibits PNAG-containing microbial biofilm formation, thereby preventing the nosocomial infection.
The method of any one of the preceding claims, wherein the antibody is administered systemically.
The method of any one of the preceding claims, wherein the antibody is administered in a controlled release formulation.
The method of any one of the preceding claims, wherein the subject is a human.
The method of any one of the preceding claims, wherein the biofilm comprises Staphylococcus.
The method of any one of the preceding claims, wherein the antibody is a human antibody.
The method of any one of the preceding claims, wherein the antibody comprises a VH domain comprising the HCDR1, HCDR2, and HCDR3 amino acid sequences set forth in SEQ ID Nos:
- 1, 2, and 3, respectively.
The method of any one of the preceding claims, wherein the antibody comprises a VL domain comprising the LCDR1, LCDR2, and LCDR3 amino acid sequences set forth in SEQ ID Nos:
- 4, 5, and 6, respectively.
The method of any one of the preceding claims, wherein the antibody comprises the VH domain sequence set forth in SEQ ID No:
- 7.
The method of any one of the preceding claims, wherein the antibody comprises the VL domain sequence set forth in SEQ ID No:
- 8.
A method of inhibiting formation of a poly N-acetyl glucosamine (PNAG)-containing microbial biofilm on a surgical implant in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to PNAG prior to implantation of the surgical implant into the subject.
A method of inhibiting formation of PNAG-containing microbial biofilm on a substrate comprising contacting the substrate with an effective amount of an antibody that specifically binds to PNAG.
Dependencies are inferred from the claim text.